Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 7
2004 10
2005 7
2006 8
2007 9
2008 11
2009 18
2010 16
2011 11
2012 13
2013 15
2014 25
2015 21
2016 22
2017 30
2018 32
2019 43
2020 51
2021 40
2022 48
2023 42

Text availability

Article attribute

Article type

Publication date

Search Results

426 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators. Bellmunt J, et al. N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17. N Engl J Med. 2017. PMID: 28212060 Free PMC article. Clinical Trial.
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators. Hussain M, et al. N Engl J Med. 2020 Dec 10;383(24):2345-2357. doi: 10.1056/NEJMoa2022485. Epub 2020 Sep 20. N Engl J Med. 2020. PMID: 32955174 Clinical Trial.
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; KEYNOTE-361 Investigators. Powles T, et al. Lancet Oncol. 2021 Jul;22(7):931-945. doi: 10.1016/S1470-2045(21)00152-2. Epub 2021 May 26. Lancet Oncol. 2021. PMID: 34051178 Clinical Trial.
Biological Behavior and Long-Term Outcomes of Carcinoma In Situ in Upper Urinary Tract Managed by Radical Nephroureterectomy.
Inamoto T, Matsuyama H, Ibuki N, Komura K, Takahara K, Fujimoto K, Shiina H, Sakano S, Nagao K, Miyake M, Tatsumi Y, Yasumoto H, Azuma H; Nishinihon Uro-Oncology Collaborative Group. Inamoto T, et al. Among authors: fujimoto k. J Urol. 2018 Apr;199(4):933-939. doi: 10.1016/j.juro.2017.10.019. Epub 2017 Oct 14. J Urol. 2018. PMID: 29037861
Prostate diseases and microbiome in the prostate, gut, and urine.
Miyake M, Tatsumi Y, Ohnishi K, Fujii T, Nakai Y, Tanaka N, Fujimoto K. Miyake M, et al. Among authors: fujimoto k. Prostate Int. 2022 Jun;10(2):96-107. doi: 10.1016/j.prnil.2022.03.004. Epub 2022 Mar 29. Prostate Int. 2022. PMID: 35510078 Free PMC article. Review.
Active surveillance for nonmuscle invasive bladder cancer.
Miyake M, Fujimoto K, Hirao Y. Miyake M, et al. Among authors: fujimoto k. Investig Clin Urol. 2016 Jun;57 Suppl 1(Suppl 1):S4-S13. doi: 10.4111/icu.2016.57.S1.S4. Epub 2016 May 27. Investig Clin Urol. 2016. PMID: 27326406 Free PMC article. Review.
Overactive bladder induces transient hypertension.
Torimoto K, Matsumoto Y, Gotoh D, Morizawa Y, Miyake M, Samma S, Tanaka N, Hirayama A, Fujimoto K. Torimoto K, et al. Among authors: fujimoto k. BMC Res Notes. 2018 Mar 27;11(1):196. doi: 10.1186/s13104-018-3317-6. BMC Res Notes. 2018. PMID: 29580270 Free PMC article.
426 results